Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BillionToOneBLLN -0.25%15 OCF Yield % is 1.01 as of Aug. 21, 2026, which is 51% above its 10-year median of 0.67. GuruFocus rates BLLN with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, BillionToOne ranks worse than 52.83% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
BillionToOne OCF Yield % Related Terms
BillionToOne OCF Yield % Historical Data
* Premium members only.
The historical data trend for BillionToOne's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BillionToOne's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's OCF Yield % distribution charts can be found below:
* The bar in red indicates where BillionToOne's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BillionToOne (BLLN) has a OCF Yield % of 1.01 as of Aug. 21, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BillionToOne and its competitors. This is 51% above median its historical median of 0.67. Over the past decade, BillionToOne's OCF Yield % has ranged from 0.09 to 1.01. According to the industry distribution chart, BillionToOne ranks #112 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 52.8%.
Is BillionToOne's OCF Yield % too high?
BillionToOne's current OCF Yield % of 1.01 is 51% above median its 10-year median of 0.67. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 1.01. The Medical Diagnostics & Research industry median OCF Yield % is 1.40. BillionToOne's value of 1.01 is 27.6% below this industry median. Based on the distribution chart, BillionToOne ranks #112 out of 212 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, BillionToOne has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's OCF Yield % compare to TWST and SHC?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #112 out of 212 companies for OCF Yield %. This places BillionToOne in the lower half of its industry. The industry median OCF Yield % is 1.40. BillionToOne's value of 1.01 is 27.6% below this benchmark. Historically, BillionToOne's own OCF Yield % has ranged from 0.09 to 1.01 over the past decade. While the company's 10-year median is 0.67 vs. the industry median of 1.40, BillionToOne has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.40, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current OCF Yield % of 1.01 is 27.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current OCF Yield % is 1.01, which is 51% above median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current OCF Yield % of 1.01. The current OCF Yield % is 1.01, which is 51% above median its 10-year median of 0.67 and 27.6% below the Medical Diagnostics & Research industry median of 1.40. BillionToOne's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For BillionToOne (BLLN), the current OCF Yield % is 1.01 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
15GF Score
Get the complete analysis for BLLN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 
